Automate Your Wheel Strategy on ALKS
With Tiblio's Option Bot, you can configure your own wheel strategy including ALKS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ALKS
- Rev/Share 9.2154
- Book/Share 10.5002
- PB 3.1095
- Debt/Equity 0.0413
- CurrentRatio 3.6716
- ROIC 0.1624
- MktCap 5391086669.0
- FreeCF/Share 2.9734
- PFCF 10.9827
- PE 15.908
- Debt/Assets 0.0307
- DivYield 0
- ROE 0.214
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ALKS | Truist | -- | Buy | -- | $50 | Nov. 11, 2025 |
| Upgrade | ALKS | RBC Capital Mkts | Sector Perform | Outperform | -- | $44 | Sept. 26, 2025 |
| Initiation | ALKS | Wells Fargo | -- | Overweight | -- | $44 | Sept. 3, 2025 |
| Initiation | ALKS | Goldman | -- | Buy | -- | $43 | July 15, 2025 |
| Upgrade | ALKS | UBS | Neutral | Buy | -- | $42 | June 17, 2025 |
| Initiation | ALKS | Needham | -- | Buy | -- | $45 | May 28, 2025 |
| Initiation | ALKS | RBC Capital Mkts | -- | Sector Perform | -- | $40 | March 13, 2025 |
| Upgrade | ALKS | UBS | Sell | Neutral | $21 | $38 | March 4, 2025 |
| Initiation | ALKS | Deutsche Bank | -- | Buy | -- | $40 | Feb. 11, 2025 |
News
ALKS or ILMN: Which Is the Better Value Stock Right Now?
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Alkermes (ALKS) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Does Alkermes (ALKS) Have the Potential to Rally 36.3% as Wall Street Analysts Expect?
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 36.3% upside potential for Alkermes (ALKS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year?
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Alkermes (ALKS) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Read More
Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised
Published: October 29, 2025 by: Zacks Investment Research
Sentiment: Positive
ALKS tops Q3 earnings and revenue estimates as Vivitrol, Aristada and Lybalvi fuel growth; 2025 guidance raised after strong demand.
Read More
Alkermes plc (ALKS) Q3 2025 Earnings Call Transcript
Published: October 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Alkermes plc (NASDAQ:ALKS ) Q3 2025 Earnings Call October 28, 2025 8:00 AM EDT Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Richard F. Pops - Chairman & CEO Joshua Reed - Chief Financial Officer C.
Read More
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Alkermes (ALKS) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.73 per share a year ago.
Read More
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Alkermes inks $2.1B deal to acquire Avadel, adding the latter's Lumryz and new growth potential to its portfolio.
Read More
Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz
Published: October 22, 2025 by: Benzinga
Sentiment: Positive
On Wednesday, Alkermes plc (NASDAQ:ALKS) agreed to acquire Avadel Pharmaceuticals plc (NASDAQ:AVDL) for up to $20 per share in cash, which values Avadel at approximately $2.1 billion.
Read More
Alkermes plc (ALKS) M&A Call Transcript
Published: October 22, 2025 by: Seeking Alpha
Sentiment: Neutral
Alkermes plc (NASDAQ:ALKS ) M&A Call October 22, 2025 8:00 AM EDT Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Richard F. Pops - Chairman & CEO Joshua Reed - Chief Financial Officer Blair Jackson - Executive VP, Chief Risk Officer & COO Conference Call Participants Leonid Timashev - RBC Capital Markets, Research Division Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Joseph Thome - TD Cowen, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division David Amsellem - Piper Sandler & Co., Research Division Basma Radwan Ibrahim - Leerink …
Read More
Avadel Jumps On $2.1 Billion Takeover Deal. But Buyer, Alkermes, Dives.
Published: October 22, 2025 by: Investors Business Daily
Sentiment: Neutral
Shares of Alkermes and Avadel Pharmaceuticals diverged Wednesday after the former agreed to buy the latter for up to $2.1 billion.
Read More
Alkermes Appoints Joshua Reed as Chief Financial Officer
Published: September 12, 2025 by: PRNewsWire
Sentiment: Neutral
DUBLIN , Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept.
Read More
Alkermes Plc (ALKS) World Sleep Congress 2025 (Transcript)
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Alkermes plc (NASDAQ:ALKS ) World Sleep Congress 2025 Conference September 8, 2025 8:00 AM EDT Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Richard F. Pops - Chairman & CEO Craig Hopkinson - Executive VP of Research & Development and Chief Medical Officer Marcus Yountz - Vice President of Clinical Development Conference Call Participants Giuseppe Plazzi Akash Tewari - Jefferies LLC, Research Division Andrea Tan - Goldman Sachs Group, Inc., Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Ami Fadia - Needham & Company, LLC, Research Division David Amsellem - Piper …
Read More
Why Is Alkermes (ALKS) Up 4.7% Since Last Earnings Report?
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
Read More
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
ALKS beats second-quarter estimates as proprietary product sales rise 14% y/y, offsetting weaker manufacturing and royalty revenues.
Read More
Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Alkermes plc (NASDAQ:ALKS ) Q2 2025 Earnings Call July 29, 2025 8:00 AM ET Company Participants Blair C. Jackson - Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO C.
Read More
Alkermes (ALKS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Alkermes (ALKS) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.72 per share a year ago.
Read More
Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy?
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Neutral
Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.
Read More
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1
Published: July 21, 2025 by: PRNewsWire
Sentiment: Neutral
– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – – Alixorexton Demonstrated Robust and Consistent Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition at All Doses Tested – – Alixorexton Was Generally Well Tolerated at All Doses Tested – – Detailed Results to Be Presented at Upcoming World Sleep Congress – – Data Support Advancement of Alixorexton to Phase 3 Development in Narcolepsy – DUBLIN , July 21, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from …
Read More
How Much Upside is Left in Alkermes (ALKS)? Wall Street Analysts Think 33.19%
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 33.2% upside potential for Alkermes (ALKS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.
Read More
ALKS or CSLLY: Which Is the Better Value Stock Right Now?
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Alkermes (ALKS) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
– Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles – DUBLIN , June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring, including presentations largely related to its psychiatry products LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil). Several of these meetings coincided with Mental Health Awareness Month in May, an important moment to raise awareness about mental health conditions, support the millions of people living with these complex diseases, and acknowledge the critical work of …
Read More
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Negative
ALKS' earnings and revenues lag first-quarter 2025 estimates. Sales of proprietary products surpass management's expectations.
Read More
Here's What Key Metrics Tell Us About Alkermes (ALKS) Q1 Earnings
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Alkermes plc (NASDAQ:ALKS ) Q1 2025 Results Conference Call May 1, 2025 8:00 AM ET Company Participants Sandy Coombs - Senior Vice President of Corporate Affairs and Investor Relations Richard Pops - Chairman and Chief Executive Officer Todd Nichols - Senior Vice President and Chief Commercial Officer Blair Jackson - Executive Vice President and Chief Operating Officer Craig Hopkinson - Chief Medical Officer Conference Call Participants Joseph Thome - TD Cowen Charles Duncan - Cantor Fitzgerald Umer Raffat - Evercore ISI David Amsellem - Piper Sandler Marc Goodman - Leerink Partners Jason Gerberry - Bank of America Leonid Timashev - …
Read More
Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Alkermes (ALKS) came out with quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.44 per share a year ago.
Read More
Alkermes plc Reports First Quarter 2025 Financial Results
Published: May 01, 2025 by: PRNewsWire
Sentiment: Neutral
— First Quarter Revenues of $306.5 Million — — GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — — Company Reiterates 2025 Financial Expectations — DUBLIN , May 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2025. "Our first quarter financial performance provides a solid foundation to deliver on our financial guidance for the year.
Read More
About Alkermes plc (ALKS)
- IPO Date 1991-07-16
- Website https://www.alkermes.com
- Industry Biotechnology
- CEO Richard F. Pops
- Employees 1800